Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 17-(3-pyridyl)-5,16-androstadien-3beta-acetate
2. Cb 7630
3. Cb-7630
4. Cb7630
5. Zytiga
1. 154229-18-2
2. Zytiga
3. Cb7630
4. Cb-7630
5. Yonsa
6. Cb 7630
7. Abiraterone Acetate [usan]
8. 17-(3-pyridyl)-5,16-androstadien-3beta-acetate
9. Em5ocb9yj6
10. [(3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] Acetate
11. Nsc-748121
12. Nsc-749227
13. Chebi:68639
14. (3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl Acetate
15. 17-(pyridin-3-yl)androsta-5,16-dien-3beta-yl Acetate
16. (3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl Acetate
17. Abiraterone Acotate
18. 17-(3-pyridyl)androsta-5, Acetate
19. Androsta-5, 17-(3-pyridinyl)-, 3-acetate,
20. Unii-em5ocb9yj6
21. Abiraterone-acetate
22. Ncgc00186462-01
23. 3s,9s,10r,13s,14s)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol, 3-acetate
24. Abiraterone Acetate
25. Mfcd00934213
26. Zytiga (tn)
27. Abiraterone (acetate)
28. Jnj-212082
29. Abiraterone Acetate- Bio-x
30. Dsstox_cid_28969
31. Dsstox_rid_83234
32. Dsstox_gsid_49043
33. Schembl93715
34. Mls006010090
35. Chembl271227
36. Gtpl9288
37. Abiraterone Acetate (jan/usp)
38. 3beta-17-(3-pyridyl)androsta-5,16-dien-3-ol Acetate
39. Abiraterone (as Acetate)
40. Abiraterone Acetate [mi]
41. Dtxsid3049043
42. Abiraterone Acetate [jan]
43. Ex-a107
44. Abiraterone Acetate [vandf]
45. Abiraterone Acetate [mart.]
46. Bcp02949
47. Zinc3809191
48. Tox21_113589
49. Abiraterone Acetate [usp-rs]
50. Abiraterone Acetate [who-dd]
51. Bdbm50407398
52. Nsc748121
53. Nsc749227
54. S2246
55. Abiraterone Acetate, >=98% (hplc)
56. Akos015896502
57. Cs-0544
58. Ds-2007
59. Jnj 212082
60. Nsc 748121
61. Nsc 749227
62. Jnj-2012082
63. Abiraterone Acetate [orange Book]
64. Ncgc00379022-06
65. Ac-25760
66. Ba164133
67. Hy-75054
68. Smr004701235
69. Abiraterone Acetate [usp Monograph]
70. Cas-154229-18-2
71. D09701
72. 3b-acetoxy-17-(3-pyridyl)androsta-5,16-diene
73. A809510
74. 3beta-acetoxy-17-(3-pyridyl)androsta-5,16-diene
75. W-201385
76. Brd-k24048528-001-02-5
77. Q27888393
78. (3s)-3-acetoxy-17-(pyridin-3-yl)androsta-5,16-diene
79. (3?)-17-(3-pyridinyl)androsta-5,16-dien-3-yl Acetate
80. (3beta)-17-(3-pyridinyl)androsta-5,16-dien-3-ol Acetate
81. 17-(pyridin-3-yl)androsta-5,16-dien-3.beta.-yl Acetate
82. Abiraterone Acetate, United States Pharmacopeia (usp) Reference Standard
83. Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, Acetate (ester), (3beta)-
84. Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, Acetate (ester), (3.beta.)-
85. (1s,2r,5s,10r,11s,15s)-2,15-dimethyl-14-(pyridin-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-7,13-dien-5-yl Acetate
86. [(3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] Ethanoate
87. Acetic Acid [(3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-(3-pyridinyl)-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] Ester
Molecular Weight | 391.5 g/mol |
---|---|
Molecular Formula | C26H33NO2 |
XLogP3 | 5.2 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 3 |
Exact Mass | 391.251129295 g/mol |
Monoisotopic Mass | 391.251129295 g/mol |
Topological Polar Surface Area | 39.2 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 739 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Zytiga is indicated with prednisone or prednisolone for:
- the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
- the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Abiraterone Mylan is indicated with prednisone or prednisolone for:
- the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).
- the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
- the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Abiraterone Krka is indicated with prednisone or prednisolone for:
- the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5. 1)
- the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)
- the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Cytochrome P-450 Enzyme Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 ENZYMES. (See all compounds classified as Cytochrome P-450 Enzyme Inhibitors.)
Steroid Synthesis Inhibitors
Compounds that bind to and inhibit enzymes involved in the synthesis of STEROIDS. (See all compounds classified as Steroid Synthesis Inhibitors.)
L02BX03
L02BX03
L02BX03
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2014-08-13
Pay. Date : 2014-05-05
DMF Number : 28038
Submission : 2014-03-27
Status : Active
Type : II
Hubei Gedian Humanwell focuses on R&D, production, & sales of fertility regulation drugs & steroidal APIs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37965
Submission : 2023-01-16
Status : Active
Type : II
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
GDUFA
DMF Review : Complete
Rev. Date : 2014-10-13
Pay. Date : 2014-08-04
DMF Number : 26894
Submission : 2014-07-30
Status : Active
Type : II
Zach System is committed to providing Highly Customized Solutions for all your Development Programs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28412
Submission : 2014-07-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26779
Submission : 2012-12-24
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-08-09
Pay. Date : 2022-06-16
DMF Number : 27853
Submission : 2013-12-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27737
Submission : 2013-11-15
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-09-12
Pay. Date : 2014-06-27
DMF Number : 27829
Submission : 2013-12-24
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-01-14
Pay. Date : 2013-09-06
DMF Number : 27376
Submission : 2013-08-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-11-01
Pay. Date : 2013-01-10
DMF Number : 26725
Submission : 2012-11-28
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga® (abiraterone acetate), is an anticancer medication. It works by preventing androgen (male hormone) production in man.
Lead Product(s): Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Abiraterone Acetate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2020
Lead Product(s) : Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga® (abiraterone acetate), is an anticancer medication. It works by preventing androgen (male hormone) production in man...
Product Name : Abiraterone Acetate-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
June 19, 2020
Details:
Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.
Lead Product(s): Abiraterone Acetate,Prednisolone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Lead Product(s) : Abiraterone Acetate,Prednisolone
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe ...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2022
Details:
Akeega (niraparib, abiraterone acetate) is a tablet works by inhibiting approved for BRCA-mutated mCRPC in adults. The FDA has approved FoundationOne Liquid CDx as its companion diagnostic.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Akeega
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: JANSSEN BIOTECH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2024
Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : JANSSEN BIOTECH
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves FoundationOne®Liquid CDx as Companion Diagnostic for AKEEGA®
Details : Akeega (niraparib, abiraterone acetate) is a tablet works by inhibiting approved for BRCA-mutated mCRPC in adults. The FDA has approved FoundationOne Liquid CDx as its companion diagnostic.
Product Name : Akeega
Product Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2024
Details:
KPG-121 is a modulator of the CRL4CRBN complex targeting rapid ubiquitination and degradation of CK1 alpha, IKZF3 and IKZF1. It is being investigated in combination with Abiraterone for mCRPC.
Lead Product(s): Lenalidomide Analog,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: KPG-121
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2024
Lead Product(s) : Lenalidomide Analog,Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Precision Bio: PBGENE-HBV Preclinical Safety Data at EASL
Details : KPG-121 is a modulator of the CRL4CRBN complex targeting rapid ubiquitination and degradation of CK1 alpha, IKZF3 and IKZF1. It is being investigated in combination with Abiraterone for mCRPC.
Product Name : KPG-121
Product Type : Small molecule
Upfront Cash : Not Applicable
June 05, 2024
Details:
Under the agreement, Novartis obtains worldwide development and commercialization rights of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer and also its preclinical AR-V7 program.
Lead Product(s): Luxdegalutamide,Abiraterone Acetate
Therapeutic Area: Oncology Product Name: ARV-766
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,160.0 million Upfront Cash: $150.0 million
Deal Type: Licensing Agreement April 11, 2024
Lead Product(s) : Luxdegalutamide,Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : $1,160.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Novartis obtains worldwide development and commercialization rights of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer and a...
Product Name : ARV-766
Product Type : Small molecule
Upfront Cash : $150.0 million
April 11, 2024
Details:
JNJ-64091742 (niraparib) is an orally administered, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor that is currently being studied for the treatment of metastatic castrationresistant prostate cancer with BRCA alterations.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: JNJ-64091742
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2023
Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JNJ-64091742 (niraparib) is an orally administered, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor that is currently being studied for the treatment of metastatic castrationresistant prostate ca...
Product Name : JNJ-64091742
Product Type : Small molecule
Upfront Cash : Not Applicable
October 22, 2023
Details:
Lynparza (olaparib) is a first-in-class PARP inhibitor and approved in combination with abiraterone for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Lead Product(s) : Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lynparza (olaparib) is a first-in-class PARP inhibitor and approved in combination with abiraterone for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.
Product Name : Lynparza
Product Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2023
Details:
USFDA approves FoundationOne®CDx to be used as a companion diagnostic for AKEEGA (niraparib and abiraterone acetate), the first-and-only dual action tablet, which was approved for deleterious BRCA-mutated metastatic castration-resistant prostate cancer in adults.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Akeega
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for ...
Details : USFDA approves FoundationOne®CDx to be used as a companion diagnostic for AKEEGA (niraparib and abiraterone acetate), the first-and-only dual action tablet, which was approved for deleterious BRCA-mutated meta...
Product Name : Akeega
Product Type : Small molecule
Upfront Cash : Not Applicable
August 14, 2023
Details:
KEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patients with BRCA-positive mCRPC.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Akeega
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2023
Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-and-Only Dual Action Ta...
Details : KEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patients with BRCA-posi...
Product Name : Akeega
Product Type : Small molecule
Upfront Cash : Not Applicable
August 11, 2023
Details:
Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment which leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.
Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Lead Product(s) : Olaparib,Abiraterone Acetate,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment which leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and t...
Product Name : Lynparza
Product Type : Small molecule
Upfront Cash : Not Applicable
July 13, 2023
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : ABIRATERONE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 250MG
Approval Date : 2020-05-18
Application Number : 208416
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : ABIRATERONE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 2023-09-01
Application Number : 208416
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : ABIRATERONE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 250MG
Approval Date : 2019-09-27
Application Number : 212462
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : ABIRATERONE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 2021-06-25
Application Number : 212462
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : ABIRATERONE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 250MG
Approval Date : 2019-02-25
Application Number : 208371
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : ABIRATERONE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 250MG
Approval Date : 2018-10-31
Application Number : 208432
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : ABIRATERONE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 2023-01-26
Application Number : 210726
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : ABIRATERONE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 125MG
Approval Date : 2022-06-24
Application Number : 212206
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : ABIRATERONE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 250MG
Approval Date : 2018-10-31
Application Number : 208446
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : ABIRATERONE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 2020-12-14
Application Number : 208446
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
14 Sep 2024
Reply
26 Apr 2024
Reply
25 Jul 2022
Reply
18 Jul 2022
Reply
14 Jun 2022
Reply
18 Apr 2022
Reply
30 Jul 2020
Reply
02 Jul 2020
Reply
23 Nov 2019
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
We have 25 companies offering DSSTox_CID_28969
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?